Cortical blindness and seizures in a patient receiving FK506 after bone marrow transplantation

Bone Marrow Transplant. 1999 May;23(9):959-62. doi: 10.1038/sj.bmt.1701732.


A 54-year-old woman with a myelodysplastic syndrome treated with high-dose chemotherapy and an allogenic bone marrow transplant developed acute cortical blindness while receiving tacrolimus (FK506). MRI showed white matter abnormalities. After discontinuation of FK506, the patient's vision returned within 8 days. FK506 neurotoxicity is similar to cyclosporine neurotoxicity and can occur in allogenic bone marrow transplant patients treated with FK506.

Publication types

  • Case Reports

MeSH terms

  • Blindness, Cortical / chemically induced*
  • Bone Marrow Transplantation*
  • Female
  • Graft Rejection / prevention & control
  • Humans
  • Immunosuppressive Agents / adverse effects*
  • Immunosuppressive Agents / therapeutic use
  • Middle Aged
  • Seizures / chemically induced*
  • Tacrolimus / adverse effects*
  • Tacrolimus / therapeutic use
  • Transplantation, Homologous


  • Immunosuppressive Agents
  • Tacrolimus